Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Earnings Data
Report Date
Mar 03, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.65Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones such as the BLA submission for INO-3107 and cost management achievements. However, challenges persist with increased net loss and reduced cash reserves. Progress in clinical trials and pipeline advancements are promising, but financial constraints pose concerns.Company Guidance
BLA Submission for INO-3107
Inovio achieved a primary objective by completing the rolling submission of the Biologics License Application (BLA) for INO-3107, marking a significant milestone in their DNA medicine platform.
Significant Reduction in Operating Expenses
Operating expenses decreased by 22% from $27.3 million in Q3 2024 to $21.2 million in Q3 2025, demonstrating effective cost management.
Promising Clinical Data for INO-3107
INO-3107 demonstrated a 50% to 100% reduction in surgeries for most patients in clinical trials, with continued benefits observed in the second year post-treatment.
Publication of DMAb Technology in Nature Medicine
Landmark proof-of-concept data on Inovio's DNA-encoded Monoclonal Antibody technology was published, showing sustained protein production without antidrug antibodies.
Advancements in DNA Medicine Pipeline
Progress in DNA encoded protein technology with upcoming presentations and promising preclinical data, highlighting potential in treating multiple diseases.
INO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $2.15 | $2.00 | -6.98% |
Aug 12, 2025 | $1.49 | $1.70 | +14.09% |
May 13, 2025 | $1.92 | $1.88 | -2.08% |
Mar 18, 2025 | $2.10 | $1.96 | -6.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inovio Pharmaceuticals (INO) report earnings?
Inovio Pharmaceuticals (INO) is schdueled to report earning on Mar 03, 2026, TBA (Confirmed).
What is Inovio Pharmaceuticals (INO) earnings time?
Inovio Pharmaceuticals (INO) earnings time is at Mar 03, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INO EPS forecast?
INO EPS forecast for the fiscal quarter 2025 (Q4) is -0.38.
